Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
EVENTS PER QUARTER · HOVER FOR EMPLOYEE COUNTS
Johnson & Johnson has announced the elimination of 56 positions at its headquarters in New Brunswick, NJ. This decision is part of a broader restructuring effort aimed at streamlining operations. The layoffs reflect the company's ongoing adjustments to its workforce in response to changing market conditions. While specific reasons for the cuts were not detailed, they are indicative of the company's strategic realignment. The layoffs are effective immediately, impacting various roles within the organization.
Johnson & Johnson has recently laid off approximately 300 employees in New Brunswick, New Jersey, as part of a restructuring effort. The layoffs have sparked criticism regarding the company's lack of transparency about the reasons behind these job cuts. Employees and stakeholders have expressed concerns over the company's communication and the impact of these layoffs on morale and operations. This move comes amid broader challenges faced by the company in the current market environment, raising questions about its future direction and workforce stability.
Johnson & Johnson is facing impending layoffs as the company navigates budget negotiations, with CEO Johnson attributing the situation to Senate Majority Leader Schumer's actions. While specific numbers of affected employees or a timeline for the layoffs have not been disclosed, the company has indicated that these job cuts are a direct consequence of the ongoing budget discussions. The uncertainty surrounding the negotiations has raised concerns about the future workforce at Johnson & Johnson, highlighting the potential impact on operations and employee morale. Further details are expected as the situation develops.
Johnson & Johnson has indicated that it may implement layoffs in the middle of the year due to ongoing budget disputes. The company is facing financial pressures that have led to discussions about workforce reductions. While specific numbers and dates have not been disclosed, the announcement suggests that the layoffs are a response to the current budgetary challenges. This situation highlights the company's efforts to manage costs effectively in a challenging economic environment.
No one has shared a story from Johnson & Johnson yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →We'll email you the moment a new layoff is reported here.